Pau Montesinos Selected Research

Tretinoin (Retinoic Acid)

1/2021	Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia.
1/2020	Advances in the management of coagulopathy in acute promyelocytic leukemia.
11/2019	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
1/2019	An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
7/2017	Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.
5/2014	How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
3/2014	Conventional induction and post-remission therapy in APL: have we arrived?
10/2013	Acute promyelocytic leukemia: do we have a new front-line standard of treatment?
10/2011	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.
2/2011	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pau Montesinos Research Topics

Disease

78	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/2022 - 01/2008
29	Acute Promyelocytic Leukemia 01/2021 - 01/2007
16	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 02/2014
13	Leukemia 12/2021 - 01/2007
10	Neoplasms (Cancer) 01/2022 - 01/2007
10	Philadelphia Chromosome 01/2022 - 10/2012
8	Hemorrhage 01/2022 - 01/2007
8	Infections 01/2022 - 01/2007
7	Febrile Neutropenia 01/2022 - 04/2009
7	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 12/2007
6	Thrombocytopenia (Thrombopenia) 11/2021 - 01/2007
6	Pneumonia (Pneumonitis) 11/2021 - 12/2007
6	Residual Neoplasm 10/2021 - 09/2014
6	Fever (Fevers) 01/2019 - 12/2007
5	Neutropenia 01/2022 - 06/2010
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 01/2019
4	Graft vs Host Disease (Graft-Versus-Host Disease) 08/2021 - 09/2013
3	Sepsis (Septicemia) 08/2021 - 04/2015
3	Mycoses (Diseases, Fungus) 09/2019 - 07/2015
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 10/2021 - 01/2016
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2020 - 11/2010
2	Obesity 03/2020 - 01/2020
2	Thrombosis (Thrombus) 01/2020 - 01/2007
2	Aplastic Anemia (Anemia, Hypoplastic) 01/2020 - 06/2015
2	Drug-Related Side Effects and Adverse Reactions 03/2014 - 10/2013
1	Dyspnea (Shortness of Breath) 12/2021
1	COVID-19 10/2021
1	Respiratory Insufficiency (Respiratory Failure) 08/2021
1	Disseminated Intravascular Coagulation 01/2021
1	Death (Near-Death Experience) 01/2021
1	Pathologic Complete Response 12/2020

Drug/Important Bio-Agent (IBA)

23	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 02/2008
23	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2021 - 01/2007
21	AnthracyclinesIBA 01/2021 - 02/2008
9	Azacitidine (5 Azacytidine)FDA Link 05/2022 - 02/2016
8	Arsenic Trioxide (Trisenox)FDA Link 01/2020 - 08/2008
7	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 05/2018 - 04/2008
6	fms-Like Tyrosine Kinase 3IBA 06/2022 - 10/2019
5	venetoclaxIBA 03/2022 - 11/2020
5	glasdegibIBA 07/2021 - 01/2019
5	Biological ProductsIBA 01/2021 - 08/2008
4	Tyrosine Kinase InhibitorsIBA 06/2022 - 01/2019
4	gilteritinibIBA 01/2022 - 10/2019
4	Retinoic Acid Receptor alphaIBA 10/2021 - 08/2008
4	fludarabineIBA 05/2021 - 01/2018
4	Pharmaceutical PreparationsIBA 01/2021 - 01/2018
4	HLA Antigens (Human Leukocyte Antigens)IBA 01/2017 - 10/2011
3	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 06/2015 - 09/2013
3	Drug CombinationsIBA 08/2014 - 10/2013
2	enasidenibIBA 06/2022 - 11/2021
2	Decitabine FDA Link 05/2022 - 01/2021
2	midostaurinIBA 01/2022 - 01/2019
2	Imatinib Mesylate (Gleevec)FDA Link 01/2022 - 10/2012
2	RG7388IBA 01/2022 - 05/2020
2	selinexorIBA 12/2021 - 06/2021
2	Mitoxantrone (Novantrone)FDA LinkGeneric 10/2021 - 06/2010
2	SteroidsIBA 08/2021 - 09/2013
2	cc-486IBA 12/2020 - 02/2016
2	Tyrosine (L-Tyrosine)FDA Link 11/2020 - 10/2011
2	Phosphotransferases (Kinase)IBA 11/2020 - 11/2012
2	quizartinibIBA 03/2020 - 01/2019
2	AnticoagulantsIBA 01/2020 - 01/2007
2	Daunorubicin (Cerubidine)FDA LinkGeneric 03/2019 - 01/2019
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2018 - 01/2018
2	plerixafor FDA Link 05/2018 - 01/2018
2	Asparaginase (Elspar)FDA Link 01/2018 - 01/2017
2	Busulfan (Busulfex)FDA Link 12/2013 - 09/2013
2	Protein Isoforms (Isoforms)IBA 12/2013 - 10/2011
2	Anti-Bacterial Agents (Antibiotics)IBA 04/2009 - 12/2007
1	Adenosine Triphosphate (ATP)IBA 04/2022
1	Antineoplastic Agents (Antineoplastics)IBA 04/2022
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	ponatinibIBA 01/2022
1	Core Binding Factors (Core-Binding Factor)IBA 01/2022
1	ivosidenibIBA 01/2022
1	sapacitabineIBA 12/2021
1	fibrin fragment D (D-dimer)IBA 12/2021
1	Biomarkers (Surrogate Marker)IBA 10/2021
1	alvocidib (flavopiridol)IBA 10/2021
1	Oxygen (Dioxygen)IBA 10/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2021
1	ArsenicIBA 01/2021
1	Histone DemethylasesIBA 12/2020

Therapy/Procedure

40	Drug Therapy (Chemotherapy) 01/2022 - 01/2007
37	Therapeutics 06/2022 - 01/2007
20	Transplantation 01/2021 - 12/2007
10	Stem Cell Transplantation 01/2021 - 08/2007
9	Induction Chemotherapy 04/2022 - 01/2012
7	Hematopoietic Stem Cell Transplantation 01/2021 - 02/2014
4	Salvage Therapy 10/2021 - 06/2019
3	Remission Induction 11/2020 - 04/2008
2	Consolidation Chemotherapy 01/2022 - 11/2018
2	Precision Medicine 10/2020 - 08/2014
1	Radiotherapy 01/2022
1	Critical Care (Surgical Intensive Care) 12/2021
1	Parenteral Nutrition 08/2021
1	Photopheresis 08/2021
1	Homologous Transplantation 01/2021